P
Peter G. Schultz
Researcher at Scripps Research Institute
Publications - 901
Citations - 96321
Peter G. Schultz is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Amino acid & Transfer RNA. The author has an hindex of 156, co-authored 893 publications receiving 89716 citations. Previous affiliations of Peter G. Schultz include Novartis Foundation & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
A General Strategy for Engineering Noncanonical Amino Acid Dependent Bacterial Growth
TL;DR: Using a tem-perature sensitive selection system, an Escherich-ia coli sliding clamp variant with an orthogonal pro-tein-protein interface is evolved, which contains a Leu273 to p-benzoylphenyl alanine (pBzF) mutation.
Journal ArticleDOI
Noncoded Amino Acid Replacement Probes of the Aspartate Aminotransferase Mechanism
TL;DR: This mutant enzyme exhibits kCat/values that are near to those of wild type enzyme; however, the kcat/vs pH profile is much sharper with similar pKas of approximately 7.5 for both the ascending and descending limbs.
Journal ArticleDOI
A Strategy for Creating Organisms Dependent on Noncanonical Amino Acids.
Weimin Xuan,Peter G. Schultz +1 more
TL;DR: This work has devised a barnase-based conditional suicide switch to further lower the escape frequency of the host cells and offers a number of attractive features for controlling host viability, including a single small-molecule-based kill switch, low escape frequency, and unaffected protein function.
Journal ArticleDOI
Rational design of antibody protease inhibitors.
Tao Liu,Guangsen Fu,Xiaozhou Luo,Yan Liu,Ying Wang,Rongsheng E. Wang,Peter G. Schultz,Feng Wang +7 more
TL;DR: This work has generated antibodies that inhibit bovine trypsin and human neutrophil elastase (HNE) with low nanomolar affinities and a highly selective humanized anti-HNE antibody with sub-nanomolar affinity.
Journal ArticleDOI
Dorsomorphin promotes human embryonic stem cell self-renewal
TL;DR: The identification of a small molecule that promotes long-term hESC self-renewal is reported, an inhibitor of bone morphogenic protein (BMP) type I receptors (ALK2, ALK3, and ALK6), which maintained the highest percentage of OCT4 positive cells in a dose-dependent manner.